Martin Huber, M.D., has served as our President and Chief Executive Officer since September 2023 and as a member of our Board of Directors since April 2020. Prior to his current role, Dr. Huber served as President and Head of R&D of Xilio Therapeutics, Inc., or Xilio, a biotechnology company, from June 2022 until September 2023. He served as Xilio’s President of R&D from August 2021 to June 2022 and as Chief Medical Officer from April 2020 to June 2022. Prior to that, he served as Senior Vice President, Chief Medical Officer at TESARO from September 2015 to January 2019, and after TESARO’s acquisition by GlaxoSmithKline, he served as Senior Vice President, Clinical, from January 2019 to April 2020. Dr. Huber has served on the board of directors of Syndax Pharmaceuticals, Inc., a biotechnology company, since September 2021. Dr. Huber received a B.S. in biology from Texas Lutheran College and an M.D. from Baylor College of Medicine.